Sugi Predict

Sugi Predict / Compounds / SCHEMBL4042767

SCHEMBL4042767

SCHEMBL4042767

COC(=O)c1n[nH]c2ncc(Br)cc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.48
▸ STAT3 P40763 1/20 0.48
▸ HIF1A Q16665 1/20 0.48
▸ KDM4C Q9H3R0 1/20 0.41
▸ TSHR P16473 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ DYRK1B Q9Y463 7/20 0.40
▸ DYRK1A Q13627 4/20 0.40
▸ NR4A2 P43354 1/20 0.38
▸ AURKA O14965 2/20 0.38
▸ DAPK3 O43293 2/20 0.38
▸ JAK2 O60674 2/20 0.38
▸ MAP4K4 O95819 2/20 0.38
▸ PAK4 O96013 2/20 0.38
▸ ABL1 P00519 2/20 0.38
▸ RET P07949 2/20 0.38
▸ FGFR1 P11362 2/20 0.38
▸ PDGFRA P16234 2/20 0.38
▸ FLT1 P17948 2/20 0.38
▸ LTK P29376 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14002611 0.86 KDM4E (0.50) KDM4ETSHRMAPK1ELANEOPRK1
SCHEMBL12168140 0.86 ALDH1A1 (0.41) KDM4ESTAT3HIF1ADYRK1BDYRK1A
SCHEMBL16517094 0.83 KDM4E (0.49) KDM4ESTAT3HIF1AKDM4CTSHR
SCHEMBL4043643 0.83 DYRK1B (0.46) KDM4EDYRK1BDYRK1AAURKADAPK3
SCHEMBL29495723 0.82 MEN1 (0.38) KDM4ESTAT3HIF1ATSHRHTT
SCHEMBL12370605 0.82 MEN1 (0.38) KDM4ESTAT3HIF1ATSHRHTT
SCHEMBL16517041 0.82 KDM4E (0.48) KDM4ESTAT3HIF1AKDM4CDYRK1A
SCHEMBL16516455 0.82 KDM4E (0.48) KDM4ESTAT3HIF1AKDM4CTSHR
SCHEMBL12515293 0.82 KDM4E (0.48) KDM4ESTAT3HIF1AKDM4CTSHR
SCHEMBL20041453 0.82 YTHDC1 (0.48) DYRK1BDYRK1AAURKADAPK3JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025235733-A1 BIS-BICYCLOHETEROARYL MACROCYCLES AND THEIR USE BLOSSOMHILL THERAPEUTICS, INC. (US) 2025-11-13 — — WO disclosed
WO-2025133961-A1 NITROGEN-CONTAINING HETEROARYL COMPOUNDS FOR THE TREATMENT OF CHRONIC DISEASES PFIZER INC. (US) 2025-06-26 — — WO disclosed
US-12281101-B2 Bicyclic lactams and methods of use thereof GENENTECH, INC. (US) 2025-04-22 — — US disclosed
EP-3760625-B1 BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES HOFFMANN LA ROCHE (CH) 2024-03-27 — — EP disclosed
CN-111269221-B Bicyclic lactams and methods of use thereof 豪夫迈·罗氏有限公司 2023-09-26 — — CN disclosed
US-20220348559-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2022-11-03 — — US disclosed
EP-3317269-B1 BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES HOFFMANN LA ROCHE (CH) 2022-09-21 — — EP disclosed
CN-112979660-A Bicyclic lactams and methods of use thereof 豪夫迈·罗氏有限公司 2021-06-18 — — CN disclosed
US-10988459-B2 Bicyclic lactams and methods of use thereof GENENTECH, INC. (US) 2021-04-27 — — US disclosed
CN-107849023-B Bicyclic lactams and methods of use thereof 豪夫迈·罗氏有限公司 2021-03-23 — — CN disclosed
US-8450340-B2 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof SAMUMED, LLC (US) 2013-05-28 — — US disclosed
US-20110190290-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF EPITHERIX, LLC (US) 2011-08-04 — — US disclosed
US-20110190290-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF EPITHERIX, LLC (US) 2011-08-04 — — US disclosed
US-7541367-B2 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders JANSSEN PHARMACEUTICA, N.V. (BE) 2009-06-02 — — US disclosed
US-7541367-B2 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders JANSSEN PHARMACEUTICA, N.V. (BE) 2009-06-02 — — US disclosed
US-7541367-B2 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders JANSSEN PHARMACEUTICA, N.V. (BE) 2009-06-02 — — US disclosed
US-20090048249-A1 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders JANSSEN PHARMACEUTICA, N.V. (BE) 2009-02-19 — — US disclosed
US-20090048249-A1 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders JANSSEN PHARMACEUTICA, N.V. (BE) 2009-02-19 — — US disclosed
US-20090048249-A1 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders JANSSEN PHARMACEUTICA, N.V. (BE) 2009-02-19 — — US disclosed
WO-2006130673-A1 3-BENZOIMIDAZOLYL-PYRAZOLOPYRIDINES USEFUL IN TREATING KINASE DISORDERS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-12-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220348559-A1 BICYCLIC LACTAMS AND METHODS OF USE THEREOF LSS, LPXN, CYP1B1 KDM4E 3546/4885STAT3 4878/4885HIF1A 3643/4885
US-20110190290-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF BRCA1, THPO, PDXK KDM4E 1972/4885STAT3 793/4885HIF1A 1349/4885
US-10988459-B2 Bicyclic lactams and methods of use thereof LSS, LPXN, CYP1B1 KDM4E 3546/4885STAT3 4878/4885HIF1A 3643/4885
US-20090048249-A1 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders PRKDC, PRKACA, ABL1 KDM4E 3003/4885STAT3 1115/4885HIF1A 3386/4885
US-12281101-B2 Bicyclic lactams and methods of use thereof LSS, LPXN, CYP1B1 KDM4E 3546/4885STAT3 4878/4885HIF1A 3643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.